News & Events

This is a listing of clinical trials recently activated by the University of Illinois Cancer Center Clinical Trials Office for patient enrollment. Click the study links below to learn details regarding the studies on clinicaltrials.gov. You can also search for other clinical trials on our website. For more information or questions about a study, email cancertrials@uic.edu or call 312-355-5112.

---

Protocol Title: FURMO-006: A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of Osimertinib or Afatinib as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations (ALPACCA)

• Sponsor: ArriVent Biopharma, Inc
• Investigator: Frank Weinberg, MD, PhD

---

Protocol Title: CTIU2317-A082304-S2402: Perioperative Versus Adjuvant Systemic Therapy in Patients with Resectable Non-Small Cell Lung Cancer - PROSPECT LUNG

• Sponsor: Alliance
• Investigator: Frank Weinberg, MD, PhD

---

Protocol Title: IRB24-1729:  A Feasibility Trial of LHRH Agonist Discontinuation In Elderly Prostate Cancer Patients 

• Sponsor: University of Chicago
• Investigator: Natalie Reizine, MD

---

Protocol Title: A032303: Gemcitabine Alternating With INtravesical BCG Randomized Against BCG Alone for Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer (GAIN-BCG)

• Sponsor: Alliance
• Investigator: Daniel Moreira, MD

---

Protocol Title: ARTEMIDE-Gastric01: A Randomized, Phase III Study of Rilvegostomig in  Combination with Fluoropyrimidine and Trastuzumab Deruxtecan Versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First-Line Treatment of HER2-Positive Gastric Cancer

• Sponsor: AstraZeneca
• Investigator: Shikha Jain, MD

---

Protocol Title: A012303: Shortened Duration of Adjuvant Therapy in Patients with Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy with HER2 Blockade

• Sponsor: Alliance
• Investigator: Kent Hoskins, MD

---

Protocol Title:  ACNS2321: A Phase II Trial Evaluating Chemotherapy followed by Response Based Reduced Radiation Therapy for Patients with Central Nervous System Germinomas

• Sponsor: Children's Oncology Group
• Investigator: Dipti Dighe, MD

---